FK866 10mg 10mg | Purity Not Available
Adooq Bioscience
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
More Information Supplier PageFK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PagePR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.
More Information Supplier PageCefozopran is a fourth-generation cephalosporin. It would be effective against respiratory tract, urinary tract, and soft tissue infections caused by a variety of gram-positive and gram-negative bacteria in humans.
More Information Supplier PageCefozopran is a fourth-generation cephalosporin. It would be effective against respiratory tract, urinary tract, and soft tissue infections caused by a variety of gram-positive and gram-negative bacteria in humans.
More Information Supplier PageA-443654, a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation.
More Information Supplier PageA-443654, a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation.
More Information Supplier PageA-443654, a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation.
More Information Supplier PageAKT inhibitor VIII is a cell-permeable and reversible quinoxaline compound that potently and selectively inhibits Akt1/Akt2 activity (IC50 = 58 nM, 210 nM, and 2.12 ?M for Akt1, Akt2, and Akt3, respectively, in in vitro kinase assays).
More Information Supplier PageAKT inhibitor VIII is a cell-permeable and reversible quinoxaline compound that potently and selectively inhibits Akt1/Akt2 activity (IC50 = 58 nM, 210 nM, and 2.12 ?M for Akt1, Akt2, and Akt3, respectively, in in vitro kinase assays).
More Information Supplier Page